Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
JAB Acquisition units begin separate trading Aug. 5 on Nasdaq

JAB Acquisition units begin separate trading Aug. 5 on Nasdaq

ReutersReuters2026/08/04 15:47
  • JAB Acquisition will allow separate trading of its 17.25 million IPO units starting Aug. 5, 2026.
  • Each unit includes 1 Class A ordinary share, 1 right for 1/4 share, 1 warrant to buy 1 share at USD 11.5.
  • Unseparated units keep trading as JABRU; separated securities trade as JAB, JABRR, JABRW.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JAB Acquisition Corp. I published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-085025), on August 04, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage